Back

PCSK9-Inhibitor treatment of cardiovascular high risk patients in a real-world setting

28 August 2018 (08:48 - 09:06)
Organised by:
Congress Presentation Part of: PCSK9 inhibitors - For the many or the few? Lipid-Lowering Agents ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Ursula Kassner

Charite University Hospital, Berlin (Germany)

4 More presentations in this session

Presentation thumbnail
PCSK9 Inhibitors - State of the art
Professor J. Armitage (Oxford, GB)
Slides Video
Presentation thumbnail
Benefit of LDL-C lowering with evolocumab on cardiovascular outcomes by age & sex: an analysis of the FOURIER trial
Professor P. Sever (London, GB)
Abstract Slides Video
Presentation thumbnail
Inhibition of PCSK9 reduces infarct size and arrhythmia susceptibility in cardiac ischeamia/reperfusion injury through attenuating mitochondrial dysfunction and increasing connexin43 phosphorylation
Doctor T. Priyadechawarawong (Chiang Mai, TH)
Abstract Slides Video
Presentation thumbnail
Future hurdles in PCSK9 - Inhibition.
Professor E. Stein (Cincinnati, US)
Slides Video

Access the full session

Session thumbnail
PCSK9 inhibitors - For the many or the few?

The Event

Event poster

ESC Congress 2018

28 August 2018 08:48 CET
You may be interested in
thumbnail
Congress Presentation
Where are we now? Decision-making in LDL-C lowering and CV risk
thumbnail
Webinar
Unmet needs in lipid management: treatment goals and how to achieve them
thumbnail
Webinar
New trial evidence in the field of lipid management

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources